button bars forest bayes pooled summary circles
 
deaths (OS)progression or deaths (PFS)RFS/DFS

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

versus Standard of Care (SoC)
durvalumab plus tremelimumab vs. Standard of Care (SoC) 1 certainty unassessable-6%--
nivolumab plus ipilimumab plus SoC vs. Standard of Care (SoC) 1 certainty unassessablestatistically conclusive-29% certainty unassessablestatistically conclusive-28%-

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons